Edition:
United Kingdom

PAVmed Inc (PAVM.OQ)

PAVM.OQ on NASDAQ Stock Exchange Capital Market

1.19USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$1.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
76,849
52-wk High
$5.99
52-wk Low
$0.87

Latest Key Developments (Source: Significant Developments)

Pavmed Says Initiated Resubmission On Aug. 22 Of Its 510(K) Submission For Its Carpx Product
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - PAVmed Inc ::PAVMED - NOTIFIED BY LEAD FDA BRANCH REVIEWING CO'S 510(K) SUBMISSION FOR CARPX PRODUCT THAT IT HAD NOT REACHED A CONSENSUS WITH CONSULTING FDA BRANCH.PAVMED - THE LEAD FDA BRANCH RECOMMENDED THAT CO TAKE STEPS TO EXTEND REVIEW PROCESS THROUGH RESUBMISSION OF ITS 510(K) SUBMISSION FOR CARPX PRODUCT.PAVMED SAYS INITIATED RESUBMISSION ON AUG. 22 OF ITS 510(K) SUBMISSION FOR ITS CARPX PRODUCT .  Full Article

PAVmed Provides Business Update
Wednesday, 25 Jul 2018 

July 25 (Reuters) - PAVmed Inc ::PAVMED PROVIDES BUSINESS UPDATE.PAVMED INC - SINCE LAST BUSINESS UPDATE, EXPERIENCED STRONG SURGE OF INVESTOR INTEREST IN PAVMED AND OUR PRODUCTS.PAVMED INC - RECEIVED WRITTEN CONFIRMATION THAT FDA RECEIVED CARPX 510(K) RESUBMISSION.PAVMED INC - EXPECT TO RECEIVE FDA'S RESPONSE TO CARPX RESUBMISSION BY END OF SUMMER.PAVMED INC - CONTINUE TO TARGET Q1 2019 FOR U.S. LAUNCH OF FIRST COMMERCIAL ESOCHECK PRODUCT.  Full Article

Ira Scott Greenspan Reports 4.7 Pct Stake In PAVmed Inc As Of June 26, 2018 - SEC Filing
Friday, 6 Jul 2018 

July 6 (Reuters) - PAVmed Inc ::IRA SCOTT GREENSPAN REPORTS 4.7 PERCENT STAKE IN PAVMED INC AS OF JUNE 26, 2018 - SEC FILING.IRA SCOTT GREENSPAN PREVIOUSLY REPORTED 11.7 PERCENT STAKE IN PAVMED INC AS OF JUNE 1, 2018.  Full Article

Lishan Aklog Reports 26.6 Pct Stake In PAVmed Inc As Of June 26, 2018 - SEC Filing
Friday, 6 Jul 2018 

July 6 (Reuters) - PAVmed Inc ::LISHAN AKLOG REPORTS 26.6 PERCENT STAKE IN PAVMED INC AS OF JUNE 26, 2018 - SEC FILING.LISHAN AKLOG PREVIOUSLY REPORTED 42.6 PERCENT STAKE IN PAVMED AS OF APRIL 5, 2018.  Full Article

PAVmed Q1 Adjusted Non-GAAP Loss Per Share $0.10
Tuesday, 22 May 2018 

May 22 (Reuters) - PAVmed Inc ::PAVMED REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.10.Q1 GAAP LOSS PER SHARE $0.21.REMAIN ON TARGET TO FILE RESUBMISSION RELATED TO CARPX TO U.S. FDA BY END OF MAY.PAVMED - IDENTIFIED EU NOTIFIED BODY, TAKING ADDITIONAL REQUISITE STEPS TO SUBMIT APPLICATION FOR CE MARK FOR CARPX IN EUROPE, TARGETED FOR LATE Q3.ALSO TOOK STEPS TO INITIATE A RIGHTS OFFERING WHICH CO EXPECTS TO LAUNCH THIS WEEK.COMMON STOCK HOLDERS WILL BE GRANTED ONE RIGHT TO PURCHASE A NEW UNIT CONSISTING OF A SHARE OF STOCK AND A SERIES Z WARRANT FOR $2.25.  Full Article

PAVmed Inc Files For Non Timely 10-Q
Tuesday, 15 May 2018 

May 15 (Reuters) - PAVmed Inc ::PAVMED INC FILES FOR NON TIMELY 10-Q - SEC FILING.  Full Article

Pavmed Announces Pricing Of Firm Commitment Common Stock Offering
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Pavmed Inc ::PAVMED ANNOUNCES PRICING OF FIRM COMMITMENT COMMON STOCK OFFERING.PAVMED INC - PRICING PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 2.4 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $1.80 PER SHARE​.  Full Article

PAVmed Sets Terms Of Previously Announced Rights Offering
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Pavmed Inc ::PAVMED SETS TERMS OF PREVIOUSLY ANNOUNCED RIGHTS OFFERING.PAVMED INC - ‍EACH RIGHT WILL ENTITLE HOLDER TO PURCHASE ONE NEW UNIT​.PAVMED INC - ‍EACH NEW UNIT WILL BE COMPRISED OF ONE SHARE OF COMMON STOCK AND ONE NEW SERIES Z WARRANT​.PAVMED INC - ‍EACH Z WARRANT WILL ENTITLE ITS HOLDER TO PURCHASE ONE SHARE OF COMMON STOCK FOR $3.00 PER SHARE FOR A PERIOD OF SIX YEARS​.PAVMED INC - ‍RIGHTS WILL BE EXERCISABLE AT A PRICE OF $2.25 PER NEW UNIT​.PAVMED INC - ‍RIGHTS WILL BE EXERCISABLE AT A PRICE OF $2.25 PER NEW UNIT​.  Full Article

Pavmed Files 510(K) Submission With Fda For Carpx Device To Treat Carpal Tunnel Syndrome
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Pavmed Inc ::PAVMED FILES 510(K) SUBMISSION WITH FDA FOR CARPX™ DEVICE TO TREAT CARPAL TUNNEL SYNDROME.PAVMED INC - ‍TARGETING CLEARANCE FOR 510(K) PREMARKET NOTIFICATION SUBMISSION FOR CARPX DEVICE IN FIRST HALF OF 2018​.  Full Article

Pavmed reports Q3 adjusted non-GAAP loss per share $0.13
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Pavmed Inc :Pavmed reports third quarter 2017 financial results.Q3 GAAP loss per share $0.40.Q3 adjusted non-GAAP loss per share $0.13.  Full Article

BRIEF-PAVmed Q1 Adjusted Non-GAAP Loss Per Share $0.10

* REMAIN ON TARGET TO FILE RESUBMISSION RELATED TO CARPX TO U.S. FDA BY END OF MAY